Skip to main content
OpenTrials
Completed

NCT Number: NCT01539746

Transcatheter Aortic Valve Implantation Without Predilation

The purpose of this study is to demonstrate that the avoidance of balloon valvuloplasty for predilation of the native aortic valve is associated with a reduction of the composite primary endpoint in TAVI patients with severely impaired left-ventricular ejection fraction (LVEF ≤35%).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Medicine II - Cardiology, University Hospital Bonn, Bonn, Germany

Loading trial locations.

About this study

Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical aortic valve replacement (SAVR) with now more than 50,000 implantations in patients with symptomatic severe aortic stenosis, who were considered to be at very high or prohibitive operative risk. Before deployment of transcatheter heart valves (THV), current medical practice requires right-ventricular rapid burst pacing (>180 bpm) with induction of a functional cardiac arrest for up to 30 seconds for balloon aortic valvuloplasty (BAV). This step is thought to be necessary to predilate the native aortic valve and to facilitate an accurate positioning of the THV. However, BAV has been shown to have numerous detrimental effects: i) the functional cardiac arrest induced by rapid pacing for BAV leads to transient coronary, cerebral, and renal ischemia. ii) In patients with impaired left ventricular ejection fraction, prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS), which are both associated with a high peri-procedural mortality. iii) BAV has been identified as a major source of embolization of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. iv) the local trauma in the left-ventricular outflow tract caused by BAV contributes to conduction disturbances with the need for permanent pacemaker implantation after TAVI.

A non-randomized pilot study by Grube et al. (JACC Interventions 2011) has recently shown that TAVI without BAV is feasible and safe, since self-expanding THV are able to "dilate" the stenosed aortic valve through the radial forces of the self-expanding nitinol frame, in which the prosthesis is mounted. According to the mentioned study, omitting BAV allows the delivery of the THV in a controlled fashion without hemodynamic compromise of the patient.

Patients with LVEF≤35% will be randomized (like the flip of a coin) to TAVI without BAV (experimental group) or TAVI with BAV for predilation (control group).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • LVEF ≤35%
  • Aortic valve stenosis with an aortic valve area <1 cm2 (<0,6 cm3/m2)
  • Males or females at least 18 years of age
  • Logistic EuroSCORE ≥15% and age ≥75 years or if age <75 years: logistic EuroSCORE ≥20% and/or a significant contraindication for open heart surgery (e.g., porcelain aorta or severe COPD)
  • Signed informed consent

Exclusion criteria

  • Patients with a device regulating the heart rhythm by pacing (e.g. pacemaker, resynchronization device, implanted defibrillator)
  • Patients with a pre-existing class I or class II indication for new pacemaker implantation according to the 2007 ESC guidelines
  • Lack of written informed consent, severe mental disorder, drug/alcohol addiction
  • Life expectancy < 1 year
  • Hypersensitivity or contraindication to acetyl salicyl acid, heparin, ticlopidine, clopidogrel, nitinol or sensitivity to contrast media that cannot be adequately premedicated
  • Recent myocardial infarction (STEMI within the last 3 months)
  • Left ventricular or atrial thrombus by echocardiography
  • Uncontrolled atrial fibrillation
  • Mitral or tricuspidal valvular insufficiency (> grade II)
  • Previous aortic valve replacement with mechanical valve
  • Evolutive or recent cerebrovascular event (within the last 3 months)
  • Vascular conditions that make insertion and endovascular access to the aortic valve impossible
  • Symptomatic carotid or vertebral arterial narrowing (>70%) disease
  • Abdominal or thoracic aortic aneurysm in the path of the delivery system
  • Bleeding diathesis or coagulopathy or patient refusing blood transfusion
  • Active gastritis or peptic ulcer disease
  • Severely impaired renal function, GFR < 30 ml/min
  • Participation in another drug or device study that would jeopardize the appropriate analysis of end-points of this study.
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
  • Pregnancy

Treatment and study plan

TAVI without BAV

Procedure

Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment

TAVI standard procedure

Procedure

TAVI standard procedure including BAV before valve deployment

Primary outcomes

  1. Primary composite efficacy endpoint

    Time frame: 30 days after TAVI

    Occurrence of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation at 30 days after TAVI.

Secondary outcomes

  1. Cardiovascular & all-cause mortality

    Time frame: 6 months, 12 months after TAVI

  2. Major/minor stroke

    Time frame: 6 months, 12 months after TAVI

  3. Myocardial infarction

    Time frame: 6 months, 12 months after TAVI

  4. conduction disturbances and pacemaker implantation rate

    Time frame: 6 months, 12 months after TAVI

  5. Acute kidney injury

    Time frame: 6 months, 12 months after TAVI

  6. Rate of postdilation

    Time frame: 30 days, 6 months, 12 months after TAVI

  7. Transvalvular mean gradient as assessed by echocardiography

    Time frame: 30 days, 6 months, 12 months after TAVI

  8. Re-hospitalization for symptoms of cardiac/valve-related decompensation

    Time frame: 30 days, 6 months, 12 months after TAVI

  9. Severity of periprosthetic aortic regurgitation (AR) as assessed by echocardiography, angiography, and hemodynamic measurements (AR index)

    Time frame: 30 days, 6 months, 12 months after TAVI

  10. Life-threatening/major/minor bleeding

    Time frame: 30 days, 6 months, 12 months after TAVI

  11. Vascular access complications

    Time frame: 30 days, 6 months, 12 months after TAVI

  12. Repeat procedure for valve-related dysfunction (surgical or interventional therapy)

    Time frame: 30 days, 6 months, 12 months after TAVI

Sponsors and collaborators

Lead sponsor

University Hospital, Bonn

Other

Registry information

Official study title

Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial

Acronym: SIMPLIFy TAVI

Important dates

Study start
2013
Primary completion
2019
Study completion
2019
First posted
Feb 27, 2012
Registry last updated
Nov 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.